Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
RCKT Analyst Ratings
Moderate Buy
8 Buy
8 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RCKT Stock 12 Month Forecast
Average Price Target
$8.21
▲(169.18% Upside)
| Highest Price Target$19.00 | Average Price Target$8.21 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Evercore ISI
$5
Hold
63.93%
Upside
Reiterated
08/11/25
Leerink Partners
$9
Hold
195.08%
Upside
Reiterated
08/11/25
Chardan Capital
$12→$11
Buy
260.66%
Upside
Reiterated
08/10/25
Jefferies
$2.5→$3
Hold
-1.64%
Downside
Reiterated
08/08/25
William Blair
―
Buy
―
Reiterated
08/08/25
Needham
―
Hold
―
Reiterated
08/08/25
TD Cowen
―
Hold
―
Reiterated
08/08/25
Wedbush
$32→$16
Buy
424.59%
Upside
Reiterated
08/08/25
Canaccord Genuity
$10
Buy
227.87%
Upside
Reiterated
08/07/25
LifeSci Capital
$9
Buy
195.08%
Upside
Reiterated
08/07/25
Rocket Pharmaceuticals: Strategic Focus on AAV Gene Therapy and Financial Resilience Justifies Buy RatingRocket Pharmaceucals (Nasdaq: RCKT) announced Q2 earnings and provided a corporate update. Over Q2 and recent weeks, Rocket repriorized its pipeline (NOTE HERE) to focus on the following AAV gene therapy programs: 1) RP-A501 for Danon disease, 2) RP-A601 for PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), and 3) RP-A701 for BAG3-associated dilated cardiomyopathy (BAG3-DCM). Development of its lenviral pipeline has largely been put on hold while it explores external opons, such as partnering, for RP-L102 in Fanconi anemia and RP-L301 in pyruvate kinase deficiency. However, Rocket plans on compleng the limited CMC work needed for a K resladi BLA resubmission in LAD-I before YE 2025. Management also implemented a strategic reorganizaon that included a 30% workforce reducon and other cost-saving measures, extending cash runway into Q2 2027 (NOTE HERE).
Morgan Stanley
$7
Hold
129.51%
Upside
Reiterated
08/07/25
Bank of America Securities
$9→$4
Hold
31.15%
Upside
Downgraded
07/25/25
Scotiabank
$19
Buy
522.95%
Upside
Reiterated
07/25/25
UBS
$12→$5
Buy
63.93%
Upside
Reiterated
06/17/25
J.P. Morgan
$44→$7
Hold
129.51%
Upside
Downgraded
05/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Evercore ISI
$5
Hold
63.93%
Upside
Reiterated
08/11/25
Leerink Partners
$9
Hold
195.08%
Upside
Reiterated
08/11/25
Chardan Capital
$12→$11
Buy
260.66%
Upside
Reiterated
08/10/25
Jefferies
$2.5→$3
Hold
-1.64%
Downside
Reiterated
08/08/25
William Blair
―
Buy
―
Reiterated
08/08/25
Needham
―
Hold
―
Reiterated
08/08/25
TD Cowen
―
Hold
―
Reiterated
08/08/25
Wedbush
$32→$16
Buy
424.59%
Upside
Reiterated
08/08/25
Canaccord Genuity
$10
Buy
227.87%
Upside
Reiterated
08/07/25
LifeSci Capital
$9
Buy
195.08%
Upside
Reiterated
08/07/25
Rocket Pharmaceuticals: Strategic Focus on AAV Gene Therapy and Financial Resilience Justifies Buy RatingRocket Pharmaceucals (Nasdaq: RCKT) announced Q2 earnings and provided a corporate update. Over Q2 and recent weeks, Rocket repriorized its pipeline (NOTE HERE) to focus on the following AAV gene therapy programs: 1) RP-A501 for Danon disease, 2) RP-A601 for PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), and 3) RP-A701 for BAG3-associated dilated cardiomyopathy (BAG3-DCM). Development of its lenviral pipeline has largely been put on hold while it explores external opons, such as partnering, for RP-L102 in Fanconi anemia and RP-L301 in pyruvate kinase deficiency. However, Rocket plans on compleng the limited CMC work needed for a K resladi BLA resubmission in LAD-I before YE 2025. Management also implemented a strategic reorganizaon that included a 30% workforce reducon and other cost-saving measures, extending cash runway into Q2 2027 (NOTE HERE).
Morgan Stanley
$7
Hold
129.51%
Upside
Reiterated
08/07/25
Bank of America Securities
$9→$4
Hold
31.15%
Upside
Downgraded
07/25/25
Scotiabank
$19
Buy
522.95%
Upside
Reiterated
07/25/25
UBS
$12→$5
Buy
63.93%
Upside
Reiterated
06/17/25
J.P. Morgan
$44→$7
Hold
129.51%
Upside
Downgraded
05/28/25
Best Analysts Covering Rocket Pharmaceuticals
1 Month
xxx
Success Rate
15/26 ratings generated profit
Average Return
+5.41%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.69% of your transactions generating a profit, with an average return of +5.41% per trade.
3 Months
xxx
Success Rate
15/26 ratings generated profit
Average Return
+13.11%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.69% of your transactions generating a profit, with an average return of +13.11% per trade.
1 Year
Success Rate
15/26 ratings generated profit
Average Return
+18.97%
reiterated a buy rating 10 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 57.69% of your transactions generating a profit, with an average return of +18.97% per trade.
2 Years
xxx
Success Rate
3/11 ratings generated profit
Average Return
-35.55%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 27.27% of your transactions generating a profit, with an average return of -35.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RCKT Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
15
31
31
34
11
Buy
2
5
5
5
1
Hold
1
7
9
12
11
Sell
7
8
8
1
0
Strong Sell
0
0
0
0
0
total
25
51
53
52
23
Each month's total comprises the sum of three months' worth of ratings.
RCKT Financial Forecast
RCKT Stock Forecast FAQ
What is RCKT’s average 12-month price target, according to analysts?
Based on analyst ratings, Rocket Pharmaceuticals’s 12-month average price target is 8.21.
What is RCKT’s upside potential, based on the analysts’ average price target?
Rocket Pharmaceuticals has 169.18% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RCKT a Buy, Sell or Hold?
Rocket Pharmaceuticals has a consensus rating of Moderate Buy which is based on 8 buy ratings, 8 hold ratings and 1 sell ratings.
What is Rocket Pharmaceuticals’s price target?
The average price target for Rocket Pharmaceuticals is 8.21. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $19.00 ,the lowest forecast is $2.00. The average price target represents 169.18% Increase from the current price of $3.05.
The highest analyst price target is $19.00 ,the lowest forecast is $2.00. The average price target represents 169.18% Increase from the current price of $3.05.
What do analysts say about Rocket Pharmaceuticals?
Rocket Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of RCKT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.